N
VRTX icon

Nuveen’s Vertex Pharmaceuticals VRTX Stock Holding History

Nuveen’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-20,000
Closed -$1.49M – 1623
2013
Q4 		$1.49M Buy
+20,000
New +$1.39M 0.01% 900

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen's VRTX Position: Q1 2026 in Review

Nuveen increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q1 2026, buying an estimated $19.6M and bringing the position to 1,084,495 shares worth $484M. The position accounts for 0.13% of the portfolio, ranked #137.

Nuveen first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.01B in Q2 2020. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Nuveen held 1,084,495 shares of Vertex Pharmaceuticals worth $484M as of Q1 2026.
  • Nuveen bought 42,098 Vertex Pharmaceuticals shares in Q1 2026, an estimated $19.6M.
  • Vertex Pharmaceuticals made up 0.13% of Nuveen's portfolio in Q1 2026, its #137 holding.
  • Nuveen first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Nuveen's Vertex Pharmaceuticals position peaked at $1.01B in Q2 2020.
  • 1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.